1-7 of 7
Thomas Delea
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Updated Results from a Matching-Adjusted Indirect Comparison of Efficacy Outcomes for Isatuximab Plus Pomalidomide and Dexamethasone Versus Daratumumab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma

Free
Xavier Leleu, Thomas Delea, Patricia Guyot, Aaron Moynahan, Erin Singh, Christina Tekle, Peggy L Lin
Journal: Blood
Blood (2023) 142 (Supplement 1): 6732.
https://doi.org/10.1182/blood-2023-188703
Published: 2023
Journal Articles

Real-World Study of Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma: Analysis across a Spectrum of Advanced Disease Stage Medicare Patients in the United States

Free
Thomas Delea, Aaron Moynahan, Wenzhen Ge, Xue Song, Glenn S. Kroog, Irene Noguera-Troise, Karen Rodriguez Lorenc, Qiufei Ma
Journal: Blood
Blood (2023) 142 (Supplement 1): 3773.
https://doi.org/10.1182/blood-2023-188591
Published: 2023
Journal Articles

Incidence of Second Primary Malignancies in Medicare-Insured Patients in the US with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

Free
Sikander Ailawadhi, Thomas Delea, Aaron Moynahan, Wenzhen Ge, Christian Hampp, Alexi Archambault, Ning Wu, Karen Rodriguez Lorenc, Irene Noguera-Troise, Glenn S. Kroog, Yariv Houvras, Qiufei Ma
Journal: Blood
Blood (2023) 142 (Supplement 1): 912.
https://doi.org/10.1182/blood-2023-188562
Published: 2023
Journal Articles

Real-World Experience of Voxelotor for the Management of Complications in Sickle Cell Disease

Free
Nirmish Shah, Thokozeni Lipato, Ofelia A. Alvarez, Thomas Delea, Alexander Lonshteyn, Derek Weycker, Andy Nguyen, Anne Beaubrun, Irene Agodoa
Journal: Blood
Blood (2021) 138 (Supplement 1): 2052.
https://doi.org/10.1182/blood-2021-153138
Published: 2021
Journal Articles

Economic Burden of Disease Progression Among Transplant Eligible Multiple Myeloma Patients Who Have Received at Least One Line of Therapy in the US

Free
Rafael Fonseca, MD, May Hagiwara, PhD, Sumeet Panjabi, PhD, Emre Yucel, PhD MSc, MBA, BSPharm, Jacqueline Buchanan, Thomas Delea, MBA
Journal: Blood
Blood (2019) 134 (Supplement_1): 2211.
https://doi.org/10.1182/blood-2019-123743
Published: 2019
Journal Articles

Cost-Effectiveness of Blinatumomab Versus Standard of Care in Adult Patients with Philadelphia-Chromosome-Negative B-Precursor Acute Lymphoblastic Leukemia in First Hematological Complete Remission (CR) with Minimal Residual Disease (MRD) from a US Payer Perspective

Free
Thomas Delea, MBA, MSIA, Nicholas Despiegel, Diana Boyko, Jordan Amdahl, Ze Cong, PhD MS, Jerald Radich, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4746.
https://doi.org/10.1182/blood-2018-99-115230
Published: 2018
Journal Articles

Burden of Disease Progression in Patients with Multiple Myeloma Who Have Received at Least One Line of Therapy in the US

Free
May Hagiwara, PhD, Thomas Delea, MBA, MSIA, Sumeet Panjabi, PhD, Emre Yucel, PhD MSc, MBA, BSPharm, Rafael Fonseca, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4754.
https://doi.org/10.1182/blood-2018-99-117230
Published: 2018